| abstract |
The present invention relates to a monoclonal antibody specifically binding to Vibrio vulnificus RtxA-1 protein and a use thereof. More specifically, the monoclonal antibody has high sensitivity, specificity, and susceptibility through high-affinity specific binding capacity to Vibrio vulnificus, can be favorably used to prevent and treat diseases caused by Vibrio vulnificus and related infection, and has an excellent vaccine effect, and thus can be used as an agent for preventing and/or treating Vibrio vulnificus sepsis. |